

December 2

08:30-08:35 **Opening Remarks**

08:40-09:30 **Morning Seminar 1**

Chair: Hisanori Umehara (Nagahama City Hospital)

**MS1 Thoughts on the etiology of IgG4-RD:
The interplay of autoantigens and adaptive immunity**

Shiv S. Pillai Medicine and Health Sciences and Technology at Harvard Medical School, Cambridge, US

Co-Sponsored by Gilead Sciences K.K. / Eisai Co., Ltd.

09:40-12:10 **Symposium 1: Epidemiology, pathology and pathophysiology I**

Chair: Tsutomu Chiba (Kansai Electric Power Hospital)
Yoh Zen (King's College Hospital)

S1-1 Derivation and Validation of Algorithms to Identify IgG4-Related Disease Patients Using Administrative Claims Data

Zachary S Wallace Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA / Clinical Epidemiology Program, Mongan Institute, Massachusetts General Hospital, Boston, MA, USA / Harvard Medical School, Boston, MA

S1-2 A genome-wide association study of IgG4-related disease in the Japanese population

Fumihiko Matsuda Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

S1-3 The potential roles of non-lymphocytic cells in the pathogenesis of IgG4-related disease

Lingli Dong Department of Rheumatology and Immunology, Huazhong University of Science and Technology, Wuhan, China

**S1-4 The pathology of IgG4-RD:
How and why does storiform fibrosis occur?**

Yoh Zen King's College Hospital, London, UK

S1-5 When is imaging indispensable in IgG4-RD?

Amita Sharma Department of Radiology, Massachusetts General Hospital, Boston, USA

Discussion and Q&A

Chair: Seiji Nakamura (Kyushu University)

LS1 CD4+ Cytotoxic T Lymphocytes and Human Disease

Cory A Perugino Division of Rheumatology, Allergy, and Immunology, Massachusetts
General Hospital, Boston, United States

**Co-Sponsored by Bristol-Myers Squibb K.K /
ONO PHARMACEUTICAL CO., LTD.**

Chair: Emanuel Della-Torre (Hospedale San Raffaele)
Yuzo Kodama (Kobe University)

**S2-1 B cells are important player of IgG4-Related Disease and
contributes to fibrosis and inflammation**

Hugues Allard-Chamard Department of Medecine, Université de Sherbrooke,
Sherbrooke, Canada / Ragon Institute of Massachusetts
General Hospital, Massachusetts Institute of Technology, and
Department of Medicine, Harvard University, Cambridge, USA

S2-2 T cell subset in IgG4-related disease

Shingo Nakayamada First Department of Internal Medicine, University of Occupational and
Environmental Health, Japan, Kitakyushu, Japan

S2-3 The B-lymphocyte lineage and fibrosis

Emanuel Della Torre Unit of Immunology, Rheumatology, Allergy and Rare Diseases
(UnIRAR), Ospedale San Raffaele, Milan, Italy

S2-4 Laminin 511-E8 is a Target Antigen in Autoimmune Pancreatitis

Masahiro Shiokawa Department of Gastroenterology and Hepatology, Kyoto University
Graduate School of Medicine, Kyoto, Japan

**S2-5 The immunological mechanisms involved in the pathophysiology
of type 1 autoimmune pancreatitis**

Kazushige Uchida Department of Gastroenterology and Hepatology, Kochi University,
Kochi Medical School, Nankoku, Japan

Discussion and Q&A

Chair: John H. Stone (MGH, Harvard)
Terumi Kamisawa (Komagome Hospital)

S3-1 Applying the 2019 ACR/EULAR Classification Criteria for IgG4-RD in Studies

John H. Stone Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, United States

S3-2 The Positive Predictive Value of a Very High Serum IgG4 Concentration for the Diagnosis of IgG4-Related Disease

Matthew C Baker Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, USA

S3-3 Differential diagnosis – Inflammatory Myofibroblastic Tumours and Rosai Dorfman Disease

Yoh Zen King's College Hospital, London, UK

S3-4 Distinction between IgG4-related disease and idiopathic multicentric Castleman disease

Kenji Notohara Kurashiki Central Hospital, Kurashiki, Japan

S3-5 Zachary S Wallace Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA / Clinical Epidemiology Program, Mongan Institute, Massachusetts General Hospital, Boston, MA, USA / Harvard Medical School, Boston, MA

Discussion and Q&A

Chair: Atsushi Masamune (Tohoku University)

ES1 The Fibrosis of IgG4-RD: How is it different?

Emma L Culver Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK

Co-Sponsored by Medical & Biological Laboratories Co., Ltd.

08:30-09:20 Morning Seminar 2

Chair: Takashi Akamizu (Kuma Hospital)

MS2 A role for the complement system in IgG4-related disease?

John P Atkinson

Department of Medicine/Rheumatology Division, Washington
University School of Medicine, St. Louis, United States

Co-Sponsored by Nittobo Medical Co., Ltd.

09:30-12:00 Symposium 4: Individual organ manifestation - I

Chair: Kazuichi Okazaki (Kansai Medical University)

Wen Zhang (Peking Union Medical College Hospital)

S4-1 Current perspectives on IgG4-related disease in the field of gastroenterology in Japan

Kazuichi Okazaki

Department of Gastroenterology and Hepatology, Kansai Medical
University, Osaka, Japan

S4-2 Method development of UHPLC-MS/MS methods for human IgG glycosylation profiling and the application to IgG4-related disease

I-Lin Tsai

Department of Biochemistry and Molecular Cell Biology, Taipei
Medical University, Taipei, Taiwan

S4-3 Clinical practice for Mikulicz's disease and Topics in recent years

Motohisa Yamamoto

Department of Rheumatology and Allergy, IMSUT Hospital, The
Institute of Medical Science, The University of Tokyo, Tokyo, Japan

S4-4 Demography, clinical manifestations and differential diagnosis of IgG4-related ophthalmic disease

Hiroshi Goto

Department of Ophthalmology, Tokyo Medical University, Tokyo,
Japan

S4-5 IgG4-RD in the biliary system: Current diagnosis and treatment in pts with IgG4-related sclerosing cholangitis based on the result from a recent Japanese nationwide study

kensuke kubota

Endoscopic Unit, Yokohama City University Hospital, Yokohama,
Japan

Discussion and Q&A

Chair: Yasuharu Sato (Okayama University)

LS2 Chasing My Cure: lessons learned from searching for treatments for idiopathic multicentric Castleman disease

David Fajgenbaum University of Pennsylvania

Co-Sponsored by CHUGAI PHARMACEUTICAL CO., LTD.

Chair: Takako Saeki (Nagaoka RCH)
Arezou Khosroshahi (Emory University)

S5-1 Retroperitoneal fibrosis

Ichiro Mizushima Department of Rheumatology, Kanazawa University Hospital,
Kanazawa, Japan

S5-2 Involvement of circulatory and respiratory organs in IgG4-RD

Shoko Matsui University of Toyama, Toyama, Toyama, Japan

S5-3 Using Radiology to distinguish between IgG4-RD and its mimickers in the lungs

Amita Sharma Department of Radiology, Massachusetts General Hospital, Boston, USA

S5-4 IgG4-related lymphadenopathy and the criteria for excluding mimickers

Akira Satou Department of Surgical Pathology, Aichi Medical University Hospital,
Nagakute, Japan

S5-5 Aortic and arterial involvement of IgG4-related disease

Nobukazu Ishizaka Fraternity Memorial Hospital, Tokyo, Japan

S5-6 Are two different types of pathophysiology underlying IgG4-related kidney disease at the same time?

Mitsuhiro Kawano Department of Rheumatology, Kanazawa University Graduate School
of Medical Science, Kanazawa, Japan

S5-7 IgG4-Related Kidney Disease

Lynn Cornell Department of Laboratory Medicine and Pathology, Mayo Clinic,
Rochester, Minnesota, United States

Discussion and Q&A

Evening Seminar 2: Horizon Therapeutics
“B cell-targeted therapy in IgG4-RD”

Chair: Yoshiya Tanaka (University of Occupational and Environmental Health, Japan)

ES2 B Cell Biology and IgG4-Related Disease

Shingo Nakayamada First Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan

Wen Zhang Department of Rheumatology, Peking Union Medical College, Hospital, Beijing, China

John Stone Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, United States

December 4

08:30-09:20 Morning Seminar 3

Chair: Hiroki Takahashi (Sapporo Medical University)

MS3 The unconventional mechanisms of IgE memory: how does this relate to IgG4?

Maria Curotto de Lafaille Department of Pediatrics, Immunology Institute and JFAFI
Food Allergy Institute, Mount Sinai School of Medicine, New
York, USA

Co-Sponsored by ZENYAKU KOGYO CO., LTD.

09:30-12:30 Symposium 6: Treatment guideline for IgG4-RD

Chair: Tsuneyo Mimori (Ijinkai Takeda General Hospital)
Zachary S. Wallace (Harvard University)

S6-1 Managment of IgG4-RD in the Era of Emerging Therapeutics

Arezou Khosroshahi Department of Medicine, Division of Rheumatology, Emory University
School of Medicine, Atlanta, USA

S6-2 Damage in IgG4-RD

Shigeyuki Kawa Department of Internal Medicine, Matsumoto Dental University,
Shiojiri (Nagano prefecture), Japan

S6-3 Management of Pancreatic Dysfunction in Autoimmune Pancreatitis

Phil Hart Division of Gastroenterology, Hepatology, and Nutrition, The Ohio
State University Wexner Medical Center, Columbus, United States

S6-4 An optimal glucocorticoid regimen — From the results of a multicenter surveillance —

Hajime Yoshifuji Department of Rheumatology and Clinical Immunology, Graduate
School of Medicine, Kyoto University, Kyoto, Japan

S6-5 Treatment of IgG4-related disease: experience from China

Wen Zhang Department of Rheumatology, Peking Union Medical College
Hospital, Beijing, China

S6-6 Biologics: Which Approaches Make The Most Sense Now?

John H Stone Division of Rheumatology, Allergy, and Immunology, Harvard Medical
School, Massachusetts General Hospital, Boston, Massachusetts,
United States

Discussion and Q&A

12:45-13:35 **Lunch time prestigious lecture**

Chair: Nobuyuki Miyasaka (Japan Intractable Diseases Research Foundation)

LS3-1 Regnase-1 is a key endoribonuclease involved in inflammation, immunity and metabolism

Shizuo Akira

Laboratory of Host Defense Immunology Frontier Research Center,
Osaka University, Osaka, Japan

LS3-2 Potential therapeutic targeting bridge from innate immunity to acquired immunity

Yoshiya Tanaka

University of Occupational and Environmental Health, Japan

Co-Sponsored by Eisai Co., Ltd. / Abbvie GK

13:40-13:45 **Closing Remarks**